[ad_1]
Image source,fake images
Beijing-based Kexing Biosciences develops a vaccine against the novel Kerlaiford coronavirus disease (Credit: Getty Images)
With the development and use of new corona vaccines in Western countries, China’s new local corona vaccines have also made great strides. Kexing Bio has already started shipping vaccines abroad.
The new corona virus disease vaccine, Kerlaifu, developed by Beijing-based biopharmaceutical company Kexing Biological, has arrived in Indonesia and is preparing to begin mass vaccination. 1.8 million more doses will arrive in January.
However, the Kexing Biotech vaccine has not yet completed its late testing stage. How much do people know about it?
What is the difference between Kexing Biovaccine?
The Kellyford developed by China Kexing Biotechnology is an inactivated vaccine made from killed pathogens, which induces cellular immunity primarily through antigen.
Several other vaccines, such as those from Modena and Pfizer, are all ribonucleic acid vaccines and use the principle of the RNA vaccine to extract some of the ribonucleic acid-encoded protein from the virus to make a vaccine.
Luo Dahai, Associate Professor of Infection and Immunization at Nanyang Technological University in Singapore, told the BBC: “Kerleford is a (inactivated) vaccine manufactured using a more traditional method. Inactivated vaccines are widely used and very successful, such as the rabies vaccine. “
“The RNA vaccine is a new type of vaccine and there is no successful case of mass vaccination.”
In theory, the main advantage of the Kexing Biological vaccine is that it can be stored at a normal refrigerator temperature (2-8 degrees), which has the same advantages as the viral vector vaccine developed by Oxford / AstraZeneca.
Modena’s vaccine should be stored at minus 20 degrees Celsius, while Pfizer’s vaccine should be stored at minus 70 degrees Celsius.
This means that the two vaccines, Kexing Biological and Oxford / AstraZeneca, can be used more effectively in developing countries, because those locations may not have enough low-temperature storage facilities for vaccine storage.
How is the effect?
It is difficult to say how effective the Kexing Biovaccine is. According to the medical journal “The Lancet”, the Kellyford vaccine currently only has Phase I and Phase II trial reports.
One of the report’s authors, Zhu Fengcai, deputy director of the Jiangsu Provincial Center for Disease Control and Prevention, said that clinical trials with 144 participants in the first phase and 600 participants in the second phase showed that the vaccine is safe and adequate. for emergency vaccination.
In early October, the vaccine was tested in phase three in Brazil, which is the second country with the second highest number of deaths from the new coronavirus. In November, the death of a volunteer caused the test to be suspended, but it was later discovered that the cause of death had nothing to do with the vaccine and it was resumed.
Instituto Butantan, a partner at Kexing Biosciences in Brazil, said the third phase of the test results report is expected to be released before mid-December.
Image source,fake images
Kexin Biotech’s Kerlaifu vaccine arrived in Sao Paulo, Brazil
Luo Dahai said that with the current limited information, it is difficult to comment on the effectiveness of the vaccine.
“The current preliminary data shows that Kellyford can be a very effective vaccine, but it still has to wait until the results of the third phase of the trial are confirmed.”
He said that vaccine trials are scientifically based, carried out under strictly controlled conditions with the participation of tens of thousands of people, it is the only way to determine that the vaccine is safe and effective for mass vaccination.
What is the way out?
Kexing Biotechnology said that in the new 20,000-square-meter factory, 300 million doses of vaccine can be produced annually.
Like other new corona vaccines, Kellyford also requires two doses, so based on current estimated production, 150 million people will be vaccinated, which is equivalent to more than one-tenth of the Chinese population.
However, Kexing Biotech also supplies abroad, in addition to the vaccines that have already reached Indonesia, but also to Turkey, Brazil and Chile.
The analysis also noted that the Chinese government also uses vaccines for diplomacy. Xi Jinping reportedly promised to provide US $ 2 billion in loans to African countries and US $ 1 billion in loans to buy vaccines from Latin American and Caribbean countries. , but the terms of the loans are unclear.
According to Jacob Mardell, an analyst at the Mercator Institute of China in Germany (MERICS), “China will definitely use this life-saving vaccine in exchange for commercial and diplomatic benefits. It has something that other countries need a lot.” , China will present the vaccine as a charity for adults. “
The price of the vaccine is currently unclear, but an emergency vaccination program was previously launched in Wuyi, Zhejiang. The price of the vaccine was about 400 yuan (US $ 60, £ 45).
People in Wuyi, Zhejiang queuing to receive a new corona vaccine
Hundreds of citizens in Yiwu, China line up to “snatch” the new crown vaccine “I feel like the new crown is a long way from me.”
According to the Indonesian state biopharmaceutical company Bio Farma, the Kexing Bio-Kerlafo vaccine is priced at approximately 200,000 IDR (13.6 USD, 10 GBP) in Indonesia.
Compared to the Oxford vaccine, which is priced at just $ 4, the price of the Kexing biovaccine is still high, but is lower than that of the $ 33 Modena vaccine.
Modena said the target shipment volume in 2021 is 500 million doses, and AstraZeneca said it will ship 700 million doses before the first quarter of 2021.
What vaccines are there in China?
In China’s emergency vaccination plan, nearly 1 million people have been vaccinated with the new corona vaccine from the China National Pharmaceutical Group, but the Chinese National Pharmaceutical Group has not yet released the results of the third phase of the vaccine. .
This emergency vaccination plan is extremely controversial. Professor Dale Fisher of the National University of Singapore said: “Usually the vaccine can be used urgently after the results of the phase III trial are published and analyzed.”
He said that China’s approach is “unconventional” and cannot be accepted in the West.
Most of the current COVID-19 epidemic in China has been brought under control and life is slowly returning to a “new normal.”
